1. (1) Advance a world-class nanotechnology research and development (R&D)
program; (2) Foster the transfer of new technologies into products for
commercial and public benefit; (3) Develop and sustain educational resources, a
skilled workforce, and the supporting infrastructure and tools to advance
nanotechnology; (4) Support responsible development of
nanotechnology.
4. (1) Precision microassembly for the
development of nanomaterial composites for biomedical implants and 3D
Microsystems for miniature instrumentation; (2) Development of a DNA sequencing
platform for obtaining the first entire human genome sequence for $100 USD
7. (1) The development and evaluation of new
nanotechnologies for health care; (2) The facilitation of commercialization and
testing in patients; (3) The education of a new workforce and the public at
large
10. Regenerative Medicine and Nanomedicine
Initiative (RMNI)
13. To support trans-national collaborations of
academia, clinical/public health communities and small to medium-sized
companies for nanomedicine-related research and technology development.
16. (1) Establish and standardize an analytical
cascade for nanomaterial characterization; (2) Facilitate the clinical
development and regulatory review of nanomaterials for cancer clinical trials;
(3) Identify and characterize critical parameters related to nanomaterials'
absorption, distribution, metabolism, excretion, and toxicity profiles of
nanomaterials using animal models; (4) Examine the biological and functional
characteristics of multi-component/combinatorial aspects of nanoscaled
therapeutic, molecular and clinical diagnostics, and detection platforms; (5) Engage
and facilitate academic and industrial-based knowledge sharing of nanomaterial
performance data and behavior resulting from pre-clinical testing (i.e.
physical characterization, in vitro testing, and in vivo
pharmaco- and toxicokinetics); (6) Interface with other nanotechnology efforts
19. Class 977's purpose is to provide a
cross-reference for examiners and others to search prior art. Before the establishment of Class 977,
examiners relied solely on keyword searches to find relevant information in
patent applications and issued patents.
22. (1) Nanoparticles and nanotubes should be
treated as hazardous materials; (2) Nanoparticles and nanotubes should be
treated as new substances under existing Notification of New Substances (NONS)
regulations; (3) The use of nanoparticles in environmental applications be
prohibited until further research can be conducted on their safety; (4) All
nanoparticle ingredients in food undergo a full safety assessment; (5) All
nanoparticle ingredients in food should be listed on the label
25. An independent review was conducted by the
Centre for Regulatory Studies at Victoria, Australia's Monash University titled
"A Review of Possible Impacts of Nanotechnology on Australia's Regulatory
Framework" in mid-2008.
28. In
July of 2008 the Working Party on Manufactured Nanomaterials formally recommended
a priority list of fourteen manufactured nanomaterials that should be the focus
of further investigation and listed 60 endpoints for the full characterization
of these materials.